Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 16/20 | 0.44 |
| ▸ | CCNY | Q8ND76 | 15/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14091483 | 0.90 | CDK14 (0.47) | CDK14CCNYALDH1A1HTTCNR1 | |
| SCHEMBL4994733 | 0.89 | USP2 (0.50) | CDK14CCNYALDH1A1HTTCNR1 | |
| SCHEMBL8261798 | 0.88 | CDK14 (0.49) | CDK14CCNYCNR1CNR2CCNT1 | |
| SCHEMBL5002711 | 0.88 | CDK14 (0.47) | CDK14CCNYCNR1CNR2CCNT1 | |
| SCHEMBL4997213 | 0.88 | CDK14 (0.47) | CDK14CCNYALDH1A1HTTCNR1 | |
| SCHEMBL8262703 | 0.87 | CDK14 (0.52) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8261796 | 0.86 | CDK14 (0.46) | CDK14CCNYCNR1CNR2CCNT1 | |
| SCHEMBL14091497 | 0.86 | CDK14 (0.45) | CDK14CCNYALDH1A1HTTCNR1 | |
| SCHEMBL14091493 | 0.86 | CDK14 (0.45) | CDK14CCNYALDH1A1HTTCNR1 | |
| SCHEMBL8261800 | 0.86 | CDK5 (0.46) | CDK14CCNYCNR1CNR2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | ASTEX THERAPEUTICS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | ASTEX THERAPEUTICS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | ASTEX THERAPEUTICS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| WO-2006077419-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | CDK1, CDK3, CDK2 | CDK14 25/4885CCNY 42/4885ALDH1A1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.